S&P 500   4,207.27 (-0.07%)
DOW   33,336.67 (+0.08%)
QQQ   324.19 (-0.53%)
AAPL   168.64 (-0.35%)
MSFT   287.49 (-0.58%)
META   177.59 (-0.42%)
GOOGL   118.98 (-0.60%)
AMZN   140.50 (-1.53%)
TSLA   860.88 (-2.51%)
NVDA   179.77 (-0.66%)
NIO   20.79 (+3.69%)
BABA   94.67 (+2.42%)
AMD   98.47 (-0.59%)
MU   62.47 (+1.74%)
T   18.02 (+0.06%)
CGC   3.15 (-4.26%)
GE   78.84 (+2.20%)
F   15.79 (+1.87%)
DIS   117.64 (+4.63%)
AMC   25.62 (+8.24%)
PYPL   99.14 (+0.23%)
PFE   48.23 (-3.44%)
NFLX   242.70 (-0.58%)
S&P 500   4,207.27 (-0.07%)
DOW   33,336.67 (+0.08%)
QQQ   324.19 (-0.53%)
AAPL   168.64 (-0.35%)
MSFT   287.49 (-0.58%)
META   177.59 (-0.42%)
GOOGL   118.98 (-0.60%)
AMZN   140.50 (-1.53%)
TSLA   860.88 (-2.51%)
NVDA   179.77 (-0.66%)
NIO   20.79 (+3.69%)
BABA   94.67 (+2.42%)
AMD   98.47 (-0.59%)
MU   62.47 (+1.74%)
T   18.02 (+0.06%)
CGC   3.15 (-4.26%)
GE   78.84 (+2.20%)
F   15.79 (+1.87%)
DIS   117.64 (+4.63%)
AMC   25.62 (+8.24%)
PYPL   99.14 (+0.23%)
PFE   48.23 (-3.44%)
NFLX   242.70 (-0.58%)
S&P 500   4,207.27 (-0.07%)
DOW   33,336.67 (+0.08%)
QQQ   324.19 (-0.53%)
AAPL   168.64 (-0.35%)
MSFT   287.49 (-0.58%)
META   177.59 (-0.42%)
GOOGL   118.98 (-0.60%)
AMZN   140.50 (-1.53%)
TSLA   860.88 (-2.51%)
NVDA   179.77 (-0.66%)
NIO   20.79 (+3.69%)
BABA   94.67 (+2.42%)
AMD   98.47 (-0.59%)
MU   62.47 (+1.74%)
T   18.02 (+0.06%)
CGC   3.15 (-4.26%)
GE   78.84 (+2.20%)
F   15.79 (+1.87%)
DIS   117.64 (+4.63%)
AMC   25.62 (+8.24%)
PYPL   99.14 (+0.23%)
PFE   48.23 (-3.44%)
NFLX   242.70 (-0.58%)
S&P 500   4,207.27 (-0.07%)
DOW   33,336.67 (+0.08%)
QQQ   324.19 (-0.53%)
AAPL   168.64 (-0.35%)
MSFT   287.49 (-0.58%)
META   177.59 (-0.42%)
GOOGL   118.98 (-0.60%)
AMZN   140.50 (-1.53%)
TSLA   860.88 (-2.51%)
NVDA   179.77 (-0.66%)
NIO   20.79 (+3.69%)
BABA   94.67 (+2.42%)
AMD   98.47 (-0.59%)
MU   62.47 (+1.74%)
T   18.02 (+0.06%)
CGC   3.15 (-4.26%)
GE   78.84 (+2.20%)
F   15.79 (+1.87%)
DIS   117.64 (+4.63%)
AMC   25.62 (+8.24%)
PYPL   99.14 (+0.23%)
PFE   48.23 (-3.44%)
NFLX   242.70 (-0.58%)
NASDAQ:TPTX

Turning Point Therapeutics - TPTX Stock Forecast, Price & News

$74.98
-0.06 (-0.08%)
(As of 08/11/2022 03:58 PM ET)
Add
Compare
Today's Range
$74.90
$75.10
50-Day Range
$34.16
$75.38
52-Week Range
$23.77
$82.20
Volume
27,757 shs
Average Volume
837,394 shs
Market Capitalization
$3.75 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$78.22

Turning Point Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
4.3% Upside
$78.22 Price Target
Short Interest
Bearish
5.01% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.47mentions of Turning Point Therapeutics in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$88,654 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($6.85) to ($7.61) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.36 out of 5 stars

Medical Sector

1065th out of 1,112 stocks

Pharmaceutical Preparations Industry

521st out of 544 stocks

TPTX stock logo

About Turning Point Therapeutics (NASDAQ:TPTX) Stock

Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California.

Turning Point Therapeutics Stock Performance

Shares of TPTX opened at $75.04 on Thursday. Turning Point Therapeutics has a twelve month low of $23.77 and a twelve month high of $82.20. The stock's 50 day moving average is $74.12 and its two-hundred day moving average is $46.17. The firm has a market capitalization of $3.73 billion, a PE ratio of -13.50 and a beta of -0.18.

Turning Point Therapeutics (NASDAQ:TPTX - Get Rating) last announced its quarterly earnings data on Monday, August 8th. The company reported ($2.48) earnings per share for the quarter, missing analysts' consensus estimates of ($1.70) by ($0.78). The business had revenue of $0.12 million during the quarter, compared to the consensus estimate of $2.27 million. During the same quarter in the previous year, the company earned ($1.14) earnings per share. The company's quarterly revenue was down 97.7% compared to the same quarter last year. On average, sell-side analysts predict that Turning Point Therapeutics will post -6.85 EPS for the current year.

Wall Street Analysts Forecast Growth

TPTX has been the subject of a number of recent analyst reports. The Goldman Sachs Group decreased their price target on Turning Point Therapeutics from $143.00 to $116.00 and set a "buy" rating for the company in a report on Tuesday, May 24th. Cowen cut Turning Point Therapeutics from an "outperform" rating to a "market perform" rating in a research report on Monday, June 6th. HC Wainwright cut Turning Point Therapeutics from a "buy" rating to a "neutral" rating and cut their target price for the stock from $161.00 to $76.00 in a research report on Monday, June 6th. Wells Fargo & Company cut Turning Point Therapeutics from an "overweight" rating to an "equal weight" rating and set a $76.00 price target on the stock. in a research report on Friday, June 3rd. Finally, Bank of America initiated coverage on Turning Point Therapeutics in a research report on Friday, May 20th. They issued a "buy" rating and a $58.00 price target on the stock. Nine investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, Turning Point Therapeutics has a consensus rating of "Hold" and an average price target of $78.22.

Insider Buying and Selling at Turning Point Therapeutics

In other news, CFO Paolo Tombesi sold 1,183 shares of the business's stock in a transaction that occurred on Wednesday, July 27th. The stock was sold at an average price of $74.94, for a total transaction of $88,654.02. Following the sale, the chief financial officer now owns 28,700 shares of the company's stock, valued at approximately $2,150,778. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 8.60% of the stock is owned by corporate insiders.

Receive TPTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Turning Point Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TPTX Stock News Headlines

Analyst Ratings for Turning Point
Expert Ratings for Turning Point
See More Headlines
Receive TPTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Turning Point Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TPTX Company Calendar

Last Earnings
8/08/2022
Today
8/11/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TPTX
Fax
N/A
Employees
250
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$78.22
High Stock Price Forecast
$116.00
Low Stock Price Forecast
$45.00
Forecasted Upside/Downside
+4.3%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
12 Analysts

Profitability

Net Income
$-236,550,000.00
Pretax Margin
-33,959.03%

Debt

Sales & Book Value

Annual Sales
$30.83 million
Book Value
$15.84 per share

Miscellaneous

Free Float
45,395,000
Market Cap
$3.75 billion
Optionable
Not Optionable
Beta
-0.18

Key Executives














TPTX Stock - Frequently Asked Questions

Should I buy or sell Turning Point Therapeutics stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Turning Point Therapeutics in the last year. There are currently 9 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" TPTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TPTX, but not buy additional shares or sell existing shares.
View TPTX analyst ratings
or view top-rated stocks.

What is Turning Point Therapeutics' stock price forecast for 2022?

12 brokers have issued 1 year price targets for Turning Point Therapeutics' shares. Their TPTX share price forecasts range from $45.00 to $116.00. On average, they anticipate the company's stock price to reach $78.22 in the next twelve months. This suggests a possible upside of 4.3% from the stock's current price.
View analysts price targets for TPTX
or view top-rated stocks among Wall Street analysts.

How have TPTX shares performed in 2022?

Turning Point Therapeutics' stock was trading at $47.70 at the beginning of the year. Since then, TPTX stock has increased by 57.2% and is now trading at $75.00.
View the best growth stocks for 2022 here
.

Are investors shorting Turning Point Therapeutics?

Turning Point Therapeutics saw a drop in short interest in July. As of July 15th, there was short interest totaling 2,130,000 shares, a drop of 25.5% from the June 30th total of 2,860,000 shares. Based on an average trading volume of 1,830,000 shares, the short-interest ratio is currently 1.2 days. Currently, 5.0% of the company's stock are short sold.
View Turning Point Therapeutics' Short Interest
.

When is Turning Point Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our TPTX earnings forecast
.

How were Turning Point Therapeutics' earnings last quarter?

Turning Point Therapeutics, Inc. (NASDAQ:TPTX) issued its quarterly earnings results on Monday, August, 8th. The company reported ($2.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.70) by $0.78. The business had revenue of $0.12 million for the quarter, compared to analysts' expectations of $2.27 million. Turning Point Therapeutics's quarterly revenue was down 97.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.14) EPS.

What other stocks do shareholders of Turning Point Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Turning Point Therapeutics investors own include NVIDIA (NVDA), Main Street Capital (MAIN), OPKO Health (OPK), Boeing (BA), General Motors (GM), AbbVie (ABBV), Gilead Sciences (GILD), GSK (GSK), Johnson & Johnson (JNJ) and Livongo Health (LVGO).

When did Turning Point Therapeutics IPO?

(TPTX) raised $167 million in an IPO on Wednesday, April 17th 2019. The company issued 9,300,000 shares at a price of $18.00 per share. Goldman Sachs, SVB Leerink and Wells Fargo Securities served as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Turning Point Therapeutics' stock symbol?

Turning Point Therapeutics trades on the NASDAQ under the ticker symbol "TPTX."

Who are Turning Point Therapeutics' major shareholders?

Turning Point Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Alpine Associates Management Inc. (2.07%), Versor Investments LP (1.26%), Candriam S.C.A. (0.99%), Healthcare of Ontario Pension Plan Trust Fund (0.53%), JPMorgan Chase & Co. (0.46%) and Frontier Capital Management Co. LLC (0.39%). Insiders that own company stock include Andrew John Partridge, Annette North, Athena Countouriotis, Brian Lee Baker, Jingrong Jean Cui, Mark J Alles, Mohammad Hirmand, Paolo Tombesi, Siegfried Reich, Simeon George and Yi Larson.
View institutional ownership trends
.

How do I buy shares of Turning Point Therapeutics?

Shares of TPTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Turning Point Therapeutics' stock price today?

One share of TPTX stock can currently be purchased for approximately $75.00.

How much money does Turning Point Therapeutics make?

Turning Point Therapeutics (NASDAQ:TPTX) has a market capitalization of $3.76 billion and generates $30.83 million in revenue each year. The company earns $-236,550,000.00 in net income (profit) each year or ($6.90) on an earnings per share basis.

How many employees does Turning Point Therapeutics have?

The company employs 250 workers across the globe.

How can I contact Turning Point Therapeutics?

Turning Point Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. The official website for the company is www.tptherapeutics.com. The company can be reached via phone at (858) 926-5251 or via email at jim.mazzola@tptherapeutics.com.

This page (NASDAQ:TPTX) was last updated on 8/11/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.